Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia.

Trends in immunology·2018

Same author

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

Blood·2018

Same author

Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.

Cancer research·2018

Same author

Foxm1 controls a pro-stemness microRNA network in neural stem cells.

Scientific reports·2018

Same author

Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.

Leukemia·2018

Same author

Hematopoietic Stem Cell Transplantation in Thalassemia.

Hematology/oncology clinics of North America·2018

Search research articles

相关实验视频

Updated: Jan 9, 2026

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

使用基因组学来完善儿科AML风险分层的细化.

Martina Pigazzi^1,2, Soheil Meshinchi³, Franco Locatelli^4,5

¹Department of Women's and Children's Health, Onco-hematology Lab and Clinic, University of Padova, Padova, Italy.

Hematology. American Society of Hematology. Education Program

|December 5, 2025

概括

基因组学的进步提高了对儿科急性髓性白血病 (AML) 的理解. 识别特定的遗传变异和向疗法提供了个性化的治疗策略,以获得更好的结果.

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

相关实验视频

Last Updated: Jan 9, 2026

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

科学领域:

基因组学就是基因组学.
儿科瘤学儿科瘤学
分子生物学分子生物学

背景情况:

在过去的二十年中,基因组技术显著提高了对儿科急性髓性白血病 (AML) 的理解.
细胞遗传检测检测到约75%的儿科AML病例中的结构变化,有助于风险评估.
下一代测序揭示了神秘的融合和突变,影响了疾病生物学和治疗反应.

研究的目的:

审查儿科AML不断变化的遗传情景.
突出新型遗传亚型及其临床影响.
讨论针对儿童AML的向治疗的潜力和挑战.

主要方法:

审查最近的基因组技术及其在儿科AML研究中的应用.
鉴定出基因变异的分析,包括特定的融合 (NUP98::NSD1,CBFA2T3::GLIS2,KMT2A) 和突变 (NPM1,WT1,DNMT3A,TP53).
讨论新兴的向疗法 (FLT3,BCL2,脑膜抑制剂).

主要成果:

特定的遗传融合定义了独特的儿童AML亚型,具有不同的临床结果.
某些NPM1异型和WT1,DNMT3A和TP53中的突变会影响患者的预后.
针对性疗法对个性化治疗有希望,但由于AML的复杂性,面临整合挑战.

结论:

儿科AML的遗传复杂性需要进一步的研究来确定预后生物标志物.
个性化治疗需要准确预测治疗反应和有效的监测策略.
合作努力对于验证生物标志物和优化小儿AML新药组合至关重要.